Consun Pharmaceutical Group Limited (HKG:1681)

Market Cap	9.36B
Revenue (ttm)	3.16B
Net Income (ttm)	968.88M
Shares Out	832.53M
EPS (ttm)	1.16
PE Ratio	9.69
Forward PE	8.27
Dividend	0.60 (5.33%)
Ex-Dividend Date	Jun 10, 2025

Volume	280,000
Average Volume	2,846,879
Open	11.24
Previous Close	11.24
Day's Range	11.06 - 11.24
52-Week Range	5.26 - 11.74
Beta	0.47
RSI	64.81
Earnings Date	May 21, 2025

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 3,164
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1681

Financial Performance

In 2024, HKG:1681's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY